Candel Therapeutics Reveals Encouraging Clinical Trial Outcomes
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a clinical-stage biopharmaceutical firm, has recently showcased remarkable findings from a Phase 2a clinical trial of their experimental drug CAN-2409. This study focused on patients suffering from advanced non-small cell lung cancer (NSCLC) who had not responded adequately to immune checkpoint inhibitors (ICIs).
Study Highlights: Improved Survival Rates
The results of this trial were compelling, indicating a median overall survival (mOS) of 24.5 months among patients who received CAN-2409. These patients had previously failed multiple lines of chemotherapy and presented significant prognostic challenges, including a majority being stage IV and having low or undetectable PD-L1 expression levels.
Progressive Condition Response
Among participants with progressive disease at the start of the trial, the mOS was noted at 21.5 months. This figure starkly contrasts with the mOS of 9.8 to 11.8 months typically reported for standard treatments like docetaxel chemotherapy in similar patient demographics.
Long-Term Survival Observed
An impressive aspect of the trial was the emergence of a long tail of survival, with 37% of the patients still alive more than 2 years post-CAN-2409 administration. This highlights the potential efficacy of CAN-2409 as a treatment option in this challenging patient population.
Immunological Response to Treatment
The study also revealed notable evidence of a systemic immune response against both treated and untreated lesions—a phenomenon termed the abscopal effect. Approximately two-thirds of patients exhibited regression of uninjected tumors, suggesting a promising immune-mediated attack not only on the primary tumor but also on metastases.
Better Outcomes for Non-Squamous NSCLC Patients
Results demonstrated statistically significant improvements in overall survival for patients with non-squamous NSCLC, who showed an increased mOS of 25.4 months. This improvement is backed by immunological biomarker data, indicating that CAN-2409 may provide a more effective strategy compared to traditional treatments.
Continued Favorable Safety Profile
Candel Therapeutics emphasized that CAN-2409's treatment regime maintained a favorable safety and tolerability profile throughout the trial’s extended follow-up. No new safety concerns were noted, reinforcing its viability as a treatment option for otherwise difficult-to-treat NSCLC patients.
Promising Future for CAN-2409
Paul Peter Tak, MD, PhD, FMedSci, the President and CEO of Candel, highlighted the groundbreaking nature of these findings, suggesting that CAN-2409 could transform the treatment landscape for advanced NSCLC. The company plans to further its development program for this investigational drug, including preparation for a prospective clinical trial potentially paving the way for regulatory approval.
Further Indications from Clinical Trials
The findings from this trial add to a growing body of evidence supporting the potential use of CAN-2409 across various cancer types. Alongside NSCLC, Candel has previously reported positive survival outcomes in trials focused on pancreatic ductal adenocarcinoma, indicating a versatile application of their immunotherapy platform.
Future Directions
Encouraged by these significant results, Candel plans to advance its clinical research efforts for CAN-2409, aiming to improve treatment strategies for impacted patients. The FDA has also recognized the potential of CAN-2409 by granting Fast Track Designation for use in NSCLC patients who have not responded to traditional treatments.
Frequently Asked Questions
What is CAN-2409?
CAN-2409 is a novel investigational drug developed by Candel Therapeutics that targets advanced non-small cell lung cancer (NSCLC), particularly in patients not responding to standard therapies.
What were the trial results for CAN-2409?
The Phase 2a trial showed a median overall survival of 24.5 months, significantly higher than existing treatments for similar patient demographics.
How does CAN-2409 work?
CAN-2409 is designed to induce an individual immune response against tumors, utilizing the herpes simplex virus thymidine kinase to promote targeted cancer cell death.
What implications do the results have for NSCLC patients?
This study indicates a potentially transformative treatment modality for patients with advanced NSCLC, improving survival outcomes in a challenging patient population.
What are the next steps for Candel Therapeutics?
Candel Therapeutics intends to advance CAN-2409 into further clinical trials with the aim of obtaining regulatory approval for broader use in NSCLC treatment.
